Trial reportJournal of periodontology2013
Platelet-derived growth factor promotes periodontal regeneration in localized osseous defects: 36-month extension results from a randomized, controlled, double-masked clinical trial.
Trial report in Journal of periodontology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 54 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain
Evaluation of Clinical and Radiographic Parameters in Bony Defects Treated With Recombinant Human Platelet-derived Growth Factor in Combination With Allograft
Who cites it
54 citing papers in PubMed, 6 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Does platelet-rich fibrin enhance the outcomes of peri-implant soft tissues? A systematic review.BMC oral health · 2025Pooled it
- Recombinant Human Platelet-Derived Growth Factor: A Systematic Review of Clinical Findings in Oral Regenerative Procedures.JDR clinical and translational research · 2021Pooled it
- Medium- and long-term clinical benefits of periodontal regenerative/reconstructive procedures in intrabony defects: Systematic review and network meta-analysis of randomized controlled clinical studies.Journal of clinical periodontology · 2021Pooled it
- The use of platelet-rich fibrin to enhance the outcomes of implant therapy: A systematic review.Clinical oral implants research · 2018Pooled it
- Efficacy of Adjunctive Bioactive Materials in the Treatment of Periodontal Intrabony Defects: A Systematic Review and Meta-Analysis.BioMed research international · 2018Pooled it
- Evaluation of Recombinant Human FGF-2 and PDGF-BB in Periodontal Regeneration: A Systematic Review and Meta-Analysis.Scientific reports · 2017Pooled it
- Recombinant Pure PDGF Improves Aesthetic Results and Patient Satisfaction Following RF Microneedling: A Prospective, Randomized, Controlled Clinical Trial.Journal of cosmetic dermatology · 2025Trial
- Platelet Rich Fibrin Matrix (PRFM) and Peripheral Blood Mesenchymal Stem Cells (PBMSCs) in the management of intraosseous defects - A randomized clinical trial.Journal of applied oral science : revista FOB · 2024Trial
- Periodontal surgery using rhFGF-2 with deproteinized bovine bone mineral or rhFGF-2 alone: 2-year follow-up of a randomized controlled trial.Journal of clinical periodontology · 2021Trial
- Treatment of intrabony periodontal defects using rhFGF-2 in combination with deproteinized bovine bone mineral or rhFGF-2 alone: A 6-month randomized controlled trial.Journal of clinical periodontology · 2019Trial
- Review
- Treatment of Severe Periodontitis using Exosome-Mediated Combination Therapies: A Retrospective Cohort Study.Oral health & preventive dentistry · 2026Article
- Recombinant Amelogenin as a Potential Alternative to Enamel Matrix Derivatives in Periodontal Regeneration: A Scoping Review of Its Biological Activity, Synthesis and Delivery Systems.Clinical and experimental dental research · 2026Article
- Effect of Leukocyte- and Platelet-Rich Fibrin on Peri-Implant Mucosal Thickness in Edentulous Patients Treated with Mandibular Implant-Retained Overdentures: A Randomized Controlled Trial.Journal of clinical medicine · 2025Article
- Current Perspectives on Mesenchymal Stem Cells as a Potential Treatment for Periodontal Diseases and Conditions.Genesis (New York, N.Y. : 2000) · 2025Review
- The impact of selcopintide on periodontal regeneration in a class II furcation defect model: a radiographic and histomorphometric analysis.Clinical oral investigations · 2025Article
- Cementum attachment protein-derived peptide induces cementum formation.FASEB bioAdvances · 2025Article
- RNAseq of peripheral blood mononucleated cells exposed to platelet-rich fibrin and enamel matrix derivatives.Scientific reports · 2025Article
- Osteoprogenitor cells from non-regenerative bone show greater resistance to cellular stress than those from regenerative bone.Frontiers in cell and developmental biology · 2025Article
- From Basic Science to Clinical Practice: A Review of Current Periodontal/Mucogingival Regenerative Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundRecombinant human platelet-derived growth factor (rhPDGF) is safe and effective for the treatment of periodontal defects in short-term studies up to 6 months in duration. We now provide results from a 36-month extension study of a multicenter, randomized, controlled clinical trial evaluating the effect and long-term stability of PDGF-BB treatment in patients with localized severe periodontal osseous defects.
methodsA total of 135 participants were enrolled from six clinical centers for an extension trial. Eighty-three individuals completed the study at 36 months and were included in the analysis. The study investigated the local application of β-tricalcium phosphate scaffold matrix with or without two different dose levels of PDGF (0.3 or 1.0 mg/mL PDGF-BB) in patients possessing one localized periodontal osseous defect. Composite analysis for clinical and radiographic evidence of treatment success was defined as percentage of cases with clinical attachment level (CAL) ≥2.7 mm and linear bone growth (LBG) ≥1.1 mm.
resultsThe participants exceeding this composite outcome benchmark in the 0.3 mg/mL rhPDGF-BB group went from 62.2% at 12 months, 75.9% at 24 months, to 87.0% at 36 months compared with 39.5%, 48.3%, and 53.8%, respectively, in the scaffold control group at these same time points (P <0.05). Although there were no significant increases in CAL and LBG at 36 months among all groups, there were continued increases in CAL gain, LBG, and percentage bone fill over time, suggesting overall stability of the regenerative response.
conclusionPDGF-BB in a synthetic scaffold matrix promotes long-term stable clinical and radiographic improvements as measured by composite outcomes for CAL gain and LBG for patients possessing localized periodontal defects ( ClinicalTrials.gov no. CT01530126).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.